AEON | Jotup

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

Retrieved on:

onsdag, maj 29, 2024

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization and cost reduction plan as the Company evaluates all financing options to support next steps across its late-stage clinical pipeline for ABP-450 that targets multiple indications.

Key Points:

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization and cost reduction plan as the Company evaluates all financing options to support next steps across its late-stage clinical pipeline for ABP-450 that targets multiple indications.
“Following a strategic review of our resources, we made the decision to implement several cost reductions that will preserve cash while still supporting corporate activities.
Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs.
These cost reduction actions will also include efforts to reduce additional operating costs and are expected to be substantially completed by June 2024.

AEON Biopharma Reports First Quarter 2024 Financial Results

Retrieved on:

tisdag, maj 14, 2024

AEON, Patient, Headache, Food, Migraine, Safety, Alembic Pharmaceuticals, Interim analysis, LTD, U.S. FDA, Pharmaceutical industry

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points:

– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –
IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
Several of the late-stage clinical programs are candidates to advance into the next phase of clinical development,” commented Marc Forth, AEON’s President and Chief Executive Officer.
The study has enrolled a total of 492 patients across approximately 50 sites in the United States, Canada and Australia.
The meeting resulted in a preliminary alignment on the design and endpoints for the proposed pivotal Phase 3 trial.

JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card

Retrieved on:

fredag, mars 22, 2024

AEON, Gasoline, IDR, JCB Co., Ltd., Travel, Restaurant, Eid al-Fitr, JCB, Platinum, Financial services

TOKYO & JAKARTA, Mar 22, 2024 - (JCN Newswire) - PT JCB International Indonesia, a subsidiary of JCB International Co., Ltd. (JCB), and PT AEON Credit Service Indonesia have launched the AEON JCB Precious Card, targeting the premium segment and focusing on family needs.

Key Points:

TOKYO & JAKARTA, Mar 22, 2024 - (JCN Newswire) - PT JCB International Indonesia, a subsidiary of JCB International Co., Ltd. (JCB), and PT AEON Credit Service Indonesia have launched the AEON JCB Precious Card, targeting the premium segment and focusing on family needs.
Customers can easily apply for the AEON JCB Precious Card and approved applicants receive the card within one hour at the AEON Service Counter at all AEON Malls in Indonesia.
Takumi Takahashi, President Director, PT JCB International Indonesia, said, "JCB is proud to partner with AEON Credit Service Indonesia and launch the AEON JCB Precious Card, offering its cardmembers benefits for daily needs, shopping, dining, domestic and international travel.
We hope that the AEON JCB Precious cardmembers can enjoy the experience of a complete journey with the AEON JCB Precious Card."

AEON Credit FY2023 Revenue Up 31.8% to HK$1,623.3 Million with Healthy Sales and Receivables Growth

Retrieved on:

fredag, april 5, 2024

AEON, Policy, Apple Pay, PVC, Seemabaddha, Insurance, Plastic, Mobile app, Growth, Overalls, Bank

Profit after tax increased by 5.0% to HK$392.3 million in FY2023, with earnings per share increasing to 93.67 HK cents (FY2022: 89.22 HK cents).

Key Points:

Profit after tax increased by 5.0% to HK$392.3 million in FY2023, with earnings per share increasing to 93.67 HK cents (FY2022: 89.22 HK cents).
The Group took a number of timely initiatives during the Reporting Year to drive healthy growth in both sales and receivables for a quality portfolio that provides income, growth and resilience.
The Group achieved another year of overall sales growth of 12.4% when compared to the year ended 28th February 2023 ("FY2022" or the "Previous Year").
Looking ahead, the Group will strive to accelerate the momentum of sales and receivables growth, while improving the credit assessment and monitoring technique to maintain stable asset quality.

AEON Biopharma Provides Update on Development Pipeline

Retrieved on:

torsdag, maj 9, 2024

AEON, FDA, Post-traumatic stress disorder, Safety, SGB, Conference, Gastroparesis, Lidocaine, Migraine, IND, Patent, Patient, Torticollis, Toxicity, Pharmaceutical industry

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.

Key Points:

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.
Several of these programs are ready to advance into the next stage of clinical development.
When taking into consideration our clinical pipeline and combining it with our differentiated business model, we see a number of compelling opportunities to pursue,” said Marc Forth, President and Chief Executive Officer of AEON.
Post-Traumatic Stress Disorder (PTSD) - IND-enabling studies are already planned, which are designed to support the development of ABP-450 in PTSD.

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Retrieved on:

fredag, maj 3, 2024

AEON, Placebo, Virtual Private LAN Service, Migraine, Data, Patient, MMD, Pharmaceutical industry

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.

Key Points:

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.
These differences did not achieve statistical significance (p=0.9132 in 150 U arm; p=0.3611 in 195 U arm).
“While we were surprised and disappointed that ABP-450 did not demonstrate statistically significant superiority over placebo in this interim readout, both active arms showed a reduction in monthly migraine days directly in-line with our expectations.
“We want to express our gratitude to the patients who participated in this trial, the clinical investigators, and the AEON team for their hard work and dedication to this study.”

Nominations open for The MIDORI Prize for Biodiversity 2024

Retrieved on:

tisdag, april 16, 2024

Professional Services, Philanthropy, Environmental, Social and Governance (ESG), Environment, Sustainability, Other Philanthropy, Foundation, AEON, CBD, COP, Convention, Biology, Prize, Conference

With the aim to encourage positive action for biodiversity and inspire others by showcasing the notable work of those it honors, nominations are now invited for the MIDORI Prize for Biodiversity 2024.

Key Points:

With the aim to encourage positive action for biodiversity and inspire others by showcasing the notable work of those it honors, nominations are now invited for the MIDORI Prize for Biodiversity 2024.
The call for nominations remains open until 15 June 2024.
The MIDORI Prize, a biennial international prize co-organized by AEON Environmental Foundation and the Secretariat of the Convention on Biological Diversity (CBD), honors individuals who have made outstanding contributions to the conservation and sustainable use of biodiversity.
Established by AEON Environmental Foundation during the 2010 International Year of Biodiversity, up to now, 19 individuals from 17 countries have received the prize.

Spain Data Center Market Set to Reach $2.85 Billion by 2029: Exclusive Insights on Norway, Greece, and Spain Unveiled in Arizton Research Report

Retrieved on:

tisdag, april 9, 2024

CHICAGO, April 9, 2024 /PRNewswire/ -- The Norway Data Center Market Investments to Reach $1.87 Billion by 2029, Growing at a CAGR of 10.28% During the Forecast Period.

Key Points:

The Norway data center market will continue to witness substantial growth due to strategic investments by key players and new entrants in the market.
The Greece Data Center Market Investments to Reach $1.34 Billion by 2029, Growing at a CAGR of 9.91% During the Forecast Period.
The Greece data center market is experiencing significant investments from global colocation data center provider Digital Realty (Lamda Hellix).
The Spain Data Center Market Investments to Reach $2.85 Billion by 2029, Growing At A CAGR 6.99% During the Forecast Period.

Spain Data Center Market Set to Reach $2.85 Billion by 2029: Exclusive Insights on Norway, Greece, and Spain Unveiled in Arizton Research Report

Retrieved on:

tisdag, april 9, 2024

CHICAGO, April 9, 2024 /PRNewswire/ -- The Norway Data Center Market Investments to Reach $1.87 Billion by 2029, Growing at a CAGR of 10.28% During the Forecast Period.

Key Points:

The Norway data center market will continue to witness substantial growth due to strategic investments by key players and new entrants in the market.
The Greece Data Center Market Investments to Reach $1.34 Billion by 2029, Growing at a CAGR of 9.91% During the Forecast Period.
The Greece data center market is experiencing significant investments from global colocation data center provider Digital Realty (Lamda Hellix).
The Spain Data Center Market Investments to Reach $2.85 Billion by 2029, Growing At A CAGR 6.99% During the Forecast Period.

AEON Biopharma Announces Redemption of Public Warrants

Retrieved on:

söndag, mars 31, 2024

AEON, Transfer, Common stock, Warrant, Exercise, Common, Sale, Attention, IPO, Fair market value, Redemption, Security (finance)

At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants.

Key Points:

At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants.
Any Public Warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be delisted, void and no longer exercisable, and the holders will have no rights with respect to those Public Warrants, except to receive the Redemption Price (or as otherwise described in the redemption notice for holders who hold their Public Warrants in “street name”).
The Redemption Fair Market Value means the volume weighted average price of the Common Stock for the ten trading days immediately following the date of the notice of redemption.
Questions concerning redemption and exercise of the Public Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000.